Fuse Science EBIT per Share
The EBIT per Share of Fuse Science (DROP) as of Jul 16, 2026 is -0.05 USD. In the previous year, EBIT per Share was -23.12 USD — a change of -99.78% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.05USD
YoY
-99.78%
Last updated:
EBIT per Share of Fuse Science is 2026 -0.05 USD. EBIT per Share of Fuse Science was 2025 -23.12 USD. It decreases by -99.78% higher compared to the previous year.
Access this data via the Eulerpool API
Fuse Science Stock analysis
What does Fuse Science do? Fuse Science Inc. is a US-based company that focuses on the development and marketing of innovative technologies in the health and sports sector. The company was founded in 2008 and is headquartered in Miami Beach, Florida.
History
Fuse Science was founded by Brian Tuffin, who aimed to enhance the performance of athletes and fitness enthusiasts. In 2012, the company gained worldwide recognition by signing internationally renowned golfer Tiger Woods as its brand ambassador. This not only increased the company's visibility but also demonstrated its ability to attract stars in the sports world.
Business model
Fuse Science has an innovative business model for marketing and distributing its products. The company specializes in the production and marketing of products based on patented technologies. A crucial component of the business model is collaborating with well-known athletes and sports clubs. These ambassadors help portray the company's products as more consumer-friendly and credible. Another vital distribution channel is online commerce.
Segments
Fuse Science offers products in various segments:
1) Sports nutrition
The sports nutrition segment includes a wide range of products, such as energy bars, gels, drinks, and supplements, aimed at improving athletes' performance and accelerating their post-workout recovery.
2) Pharmaceuticals
Fuse Science also has a pharmaceutical segment focusing on the development of novel drugs. The company utilizes its patented technology to deliver medications faster into the body and enhance their effectiveness. An example of such a medication is Tegison, used in the treatment of severe skin conditions.
3) Cosmetics
Fuse Science also offers a broad range of cosmetic products. These products aim to improve skin appearance and reduce wrinkles.
Products
Fuse Science has a variety of products on the market that rely on its patented technology. Some of the most well-known products include:
1) ElectroFuse
ElectroFuse is an electrolyte drink that helps rehydrate the body after physical exertion.
2) PowerFuse
PowerFuse is a dietary supplement aimed at improving athletes' performance and accelerating their post-workout recovery.
3) LipriSe
LipriSe is a cream that helps reduce the appearance of wrinkles and age spots.
Conclusion
Fuse Science is an innovative company specializing in the development and marketing of products based on its patented technology. The company markets its products in both the sports and medical fields, aiming to enhance athletes' performance and improve people's overall health. Fuse Science has a promising future in developing new products that contribute to improving people's health and well-being. Fuse Science is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Fuse Science stock
EBIT per Share of Fuse Science is -0.05 USD in 2026.
Access this data via the Eulerpool API
Income Statement — Fuse Science
All Key Metrics — Fuse Science
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth